283
Participants
Start Date
July 31, 2011
Primary Completion Date
October 31, 2012
Study Completion Date
October 31, 2012
albiglutide (GSK716155)
subcutaneous injection administered once a week
albiglutide (GSK716155)
subcutaneous injection administered once a week
GSK Investigational Site, Bensalem
GSK Investigational Site, Lewisburg
GSK Investigational Site, Greensboro
GSK Investigational Site, Columbia
GSK Investigational Site, North Myrtle Beach
GSK Investigational Site, Simpsonville
GSK Investigational Site, Blue Ridge
GSK Investigational Site, Jacksonville
GSK Investigational Site, Orlando
GSK Investigational Site, Hallandale
GSK Investigational Site, Tampa
GSK Investigational Site, Dothan
GSK Investigational Site, Clarksville
GSK Investigational Site, McKenzie
GSK Investigational Site, Picayune
GSK Investigational Site, Gulfport
GSK Investigational Site, Lexington
GSK Investigational Site, Paducah
GSK Investigational Site, Columbus
GSK Investigational Site, Mason
GSK Investigational Site, Omaha
GSK Investigational Site, Irving
GSK Investigational Site, Houston
GSK Investigational Site, Sugarland
GSK Investigational Site, San Antonio
GSK Investigational Site, San Antonio
GSK Investigational Site, San Antonio
GSK Investigational Site, Bountiful
GSK Investigational Site, Long Beach
GSK Investigational Site, Riverside
Lead Sponsor
GlaxoSmithKline
INDUSTRY